LABT
First patient in, now the real test begins
Lakewood-Amedex Biotherapeutics says the first patient has been dosed in its Phase 2a clinical trial of Nu-3, a treatment candidate for infected diabetic foot ulcers. In biotech, that’s the moment the movie stops being about slides and starts being about patients.
Why this matters
If you own the stock, the key thing is simple: a trial that’s actively dosing patients is one step closer to generating the kind of data investors can actually price. That doesn’t mean success — biotech is still a game of suspense, cliffhangers, and occasional face-plants — but it does mean the program is advancing beyond the gatekeeping stage.
What to watch next
The obvious next checkpoint is data. Investors will be looking for signs that Nu-3 can show enough safety and activity to justify the next phase of development.
- The trial is Phase 2a, so this is still an early, high-risk chapter.
- The indication, infected diabetic foot ulcers, is a nasty clinical problem with real unmet need.
- If the readout is encouraging, it could help validate the program and the company’s pipeline story.
Big picture: in biotech, dosing the first patient is less about fireworks and more about finally pressing play on the experiment. That’s small, but it’s also where the value debate starts getting real.